SK287101B6 - Amidoxímové deriváty propénkarboxylovej kyseliny, spôsob ich prípravy a farmaceutické prípravky s ich obsahom - Google Patents

Amidoxímové deriváty propénkarboxylovej kyseliny, spôsob ich prípravy a farmaceutické prípravky s ich obsahom Download PDF

Info

Publication number
SK287101B6
SK287101B6 SK1350-2002A SK13502002A SK287101B6 SK 287101 B6 SK287101 B6 SK 287101B6 SK 13502002 A SK13502002 A SK 13502002A SK 287101 B6 SK287101 B6 SK 287101B6
Authority
SK
Slovakia
Prior art keywords
formula
compound
derivative
group
pharmaceutically acceptable
Prior art date
Application number
SK1350-2002A
Other languages
English (en)
Slovak (sk)
Other versions
SK13502002A3 (sk
Inventor
Nagy P�Ter Liter�Ti
Bal�Zs S�Megi
K�Lm�N Tak�Cs
Original Assignee
N-Gene Research Laboratories Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU0001178A external-priority patent/HU0001178D0/hu
Priority claimed from HU0100987A external-priority patent/HU227116B1/hu
Application filed by N-Gene Research Laboratories Inc. filed Critical N-Gene Research Laboratories Inc.
Publication of SK13502002A3 publication Critical patent/SK13502002A3/sk
Publication of SK287101B6 publication Critical patent/SK287101B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/40—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C07D273/04—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Psychology (AREA)
SK1350-2002A 2000-03-20 2001-03-13 Amidoxímové deriváty propénkarboxylovej kyseliny, spôsob ich prípravy a farmaceutické prípravky s ich obsahom SK287101B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU0001178A HU0001178D0 (en) 2000-03-20 2000-03-20 New propene-carbon acid-amidoxim derivatives, process for their production and medicaments containing the same
HU0100987A HU227116B1 (en) 2001-03-07 2001-03-07 New propenecarboxylic acid amidoxime derivatives, process for their preparation and pharmaceutical compositions containing them
PCT/HU2001/000029 WO2001070674A1 (fr) 2000-03-20 2001-03-13 Derives amidoxime d'acide propenecarboxylique, leur procede de preparation, et compositions pharmaceutiques renfermant ces derives

Publications (2)

Publication Number Publication Date
SK13502002A3 SK13502002A3 (sk) 2003-02-04
SK287101B6 true SK287101B6 (sk) 2009-12-07

Family

ID=89979102

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1350-2002A SK287101B6 (sk) 2000-03-20 2001-03-13 Amidoxímové deriváty propénkarboxylovej kyseliny, spôsob ich prípravy a farmaceutické prípravky s ich obsahom

Country Status (25)

Country Link
US (2) US6887872B2 (fr)
EP (1) EP1268407B1 (fr)
JP (1) JP2003528073A (fr)
KR (1) KR100679364B1 (fr)
CN (1) CN1232503C (fr)
AT (1) ATE265998T1 (fr)
AU (1) AU783393B2 (fr)
BR (1) BR0109430A (fr)
CA (1) CA2404128C (fr)
CZ (1) CZ20023110A3 (fr)
DE (1) DE60103140T2 (fr)
DK (1) DK1268407T3 (fr)
ES (1) ES2220753T3 (fr)
HK (1) HK1053826B (fr)
IL (1) IL151669A0 (fr)
MX (1) MXPA02009216A (fr)
NO (1) NO328650B1 (fr)
NZ (1) NZ521792A (fr)
PL (1) PL358393A1 (fr)
PT (1) PT1268407E (fr)
RU (1) RU2264387C2 (fr)
SI (1) SI1268407T1 (fr)
SK (1) SK287101B6 (fr)
TR (1) TR200401912T4 (fr)
WO (1) WO2001070674A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040151785A1 (en) * 1998-10-06 2004-08-05 Diamedica Inc. Method for treating insulin resistance through hepatic nitric oxide
BRPI0414136A (pt) * 2003-09-04 2006-10-31 Aventis Pharma Inc indóis substituìdos como inibidores de poli(adp-ribose) polimerase (parp)
WO2006137510A1 (fr) 2005-06-24 2006-12-28 Ono Pharmaceutical Co., Ltd. Agent pour réduire le saignement lors de troubles cérébrovasculaires
DE102006050516A1 (de) * 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
JP5495331B2 (ja) * 2007-06-01 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション γセクレターゼ修飾因子
WO2008154129A1 (fr) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Compositions pharmaceutiques et procédé permettant de traiter, réduire, améliorer, atténuer, ou prévenir la sécheresse oculaire
JP2012508748A (ja) 2008-11-13 2012-04-12 シェーリング コーポレイション γ−セクレターゼ調節剤
HUP1100445A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
WO2013173923A1 (fr) 2012-05-25 2013-11-28 Diamedica, Inc. Formulations de kallikréine 1 de tissu humain pour l'administration parentérale et procédés associés
SI2854841T1 (sl) 2012-06-04 2017-06-30 Diamedica Inc. Glikozilacijske izooblike humanega tkivnega kalikreina-1
WO2015084752A1 (fr) * 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Modulateurs de la sécrétase gamma
FR3035105A1 (fr) * 2015-04-16 2016-10-21 Metabrain Res Derives utiles dans le traitement de l'atrophie musculaire
CA3054962A1 (fr) 2017-03-09 2018-09-13 Rick PAULS Formes posologiques de kallicreine tissulaire 1
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
CN112107594B (zh) * 2020-09-29 2021-10-26 苏州大学 共价有机纳米片材料的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU179951B (en) 1979-10-11 1983-01-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing 1,2,4-oxadiazolin-5-one derivatives and pharmaceutical compositions containing thereof
EP0039861B1 (fr) 1980-05-12 1984-08-15 Henkel Kommanditgesellschaft auf Aktien Procédé de dégradation du groupe 20-carboxy de delta 1,4-BNC (bis-nor-cholanic acid) et de dérivés stéroides apparentés et nouveaux stéroides azotés à 21 carbones
HUT54347A (en) 1989-01-10 1991-02-28 Chinoin Gyogyszer Es Vegyeszet Improved process for producing amidoximes
GB9702701D0 (en) * 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
US6291425B1 (en) * 1999-09-01 2001-09-18 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
UA65635C2 (uk) * 1998-09-03 2004-04-15 Н-Гене Кутато Кфт. НЕНАСИЧЕНІ ПОХІДНІ ГІДРОКСИМОВОЇ КИСЛОТИ, ЩО МАЮТЬ ВЛАСТИВОСТІ ІНГІБІТОРІВ NAD<sup>+</sup>-ADP-РИБОЗИЛТРАНСФЕРАЗИ
HU229875B1 (en) * 1999-01-11 2014-11-28 Agouron Pharmaceuticals Inc La Jolla Tricyclic inhibitors of poly(adp-ribose) polymerases
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
DE19921567A1 (de) * 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten

Also Published As

Publication number Publication date
CA2404128A1 (fr) 2001-09-27
US20050165019A1 (en) 2005-07-28
NO20024341L (no) 2002-11-20
ES2220753T3 (es) 2004-12-16
KR100679364B1 (ko) 2007-02-05
NO20024341D0 (no) 2002-09-11
EP1268407A1 (fr) 2003-01-02
RU2264387C2 (ru) 2005-11-20
ATE265998T1 (de) 2004-05-15
CN1426392A (zh) 2003-06-25
AU4674401A (en) 2001-10-03
WO2001070674A1 (fr) 2001-09-27
HK1053826B (zh) 2005-01-14
EP1268407B1 (fr) 2004-05-06
DE60103140D1 (de) 2004-06-09
NO328650B1 (no) 2010-04-19
CZ20023110A3 (cs) 2003-02-12
SK13502002A3 (sk) 2003-02-04
PT1268407E (pt) 2004-11-30
AU783393B2 (en) 2005-10-20
IL151669A0 (en) 2003-04-10
HK1053826A1 (en) 2003-11-07
CN1232503C (zh) 2005-12-21
CA2404128C (fr) 2011-01-04
SI1268407T1 (en) 2004-10-31
BR0109430A (pt) 2002-12-10
JP2003528073A (ja) 2003-09-24
US7151175B2 (en) 2006-12-19
MXPA02009216A (es) 2003-12-11
TR200401912T4 (tr) 2004-09-21
KR20020091144A (ko) 2002-12-05
US20030153559A1 (en) 2003-08-14
PL358393A1 (en) 2004-08-09
US6887872B2 (en) 2005-05-03
DK1268407T3 (da) 2004-09-06
DE60103140T2 (de) 2005-05-04
NZ521792A (en) 2004-06-25

Similar Documents

Publication Publication Date Title
US7151175B2 (en) Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same
EP2822548B1 (fr) Inhibiteurs de la kinase sphingosine avec base à longue chaîne
US6500823B1 (en) Unsaturated hydroximic acid derivatives as per abstract inhibitors
EP0024924B1 (fr) Sydnonimines, leur préparation et compositions pharmaceutiques les contenant
HU227116B1 (en) New propenecarboxylic acid amidoxime derivatives, process for their preparation and pharmaceutical compositions containing them
US20050203176A1 (en) Carbamates as HIV anti-viral agents
UA73557C2 (en) Amideoxyme derivatives of propenecarboxylic acid, a method for the preparation thereof and a pharmaceutical composition based thereon
US4094871A (en) 1,3,4-Benzotriazepine-2-thiones

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20120313